authors
- Gelmon, KA
- Eisenhauer, E
- Reyno, L
- Fisher, B
- Ayers, D
- Lee, U
- Hirte, Holger
- D'Aloisio, S
- Hurak, S
- Hamilton, M
- Ptaszynski, M
- Onetto, N
Phase I study of NX211 given as an intravenous infusion on days 1, 2 & 3 every 3 weeks in patients (pts) with solid tumors - an NCIC Clinical Trials Group study.
Conferences
- Overview
- Research
- Additional Document Info
- View All
Overview
status
publication date
- November 1999
has subject area
- 1112 Oncology and Carcinogenesis (FoR)
- Oncology & Carcinogenesis (Science Metrix)
published in
- Clinical Cancer Research Journal